Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications

Infectious Diseases and Therapy

Volumn 4, Issue 2, 2015, Pages 159-172

  Kaur, Kirpal ^a   Gandhi, Mona A ^a   Slish, Judianne ^a  

^a ST JOHN FISHER COLLEGE   (United States)

Author keywords

HCV; HIV; HIV HCV drug interactions

Indexed keywords

ANTIVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DASABUVIR; DELAVIRDINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; LEDIPASVIR PLUS SOFOSBUVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; OMBITASVIR; PARITAPREVIR; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REPLICATION;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84977111033     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-015-0061-2     Document Type: Review

References (46)

1. Centers for Disease Control and Prevention; Infectious diseases related to travel http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-c. Accessed Dec 2, 2014.
2. Puotia M, Rossottia R, Travia G, et al. Optimizing treatment in HIV/HCV co-infection. Dig Liver Dis. 2013;45S:S355–62.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed Dec 3, 2014.
4. Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla RM): a review of its use in the management of HIV infection. Drugs. 2010;70(17):2315–38.
5. Soriano V, Vispo E, Labarga P, et al. Viral hepatitis and HIV co-infection. Antivir Res. 2010;85(1):303–15.
6. Weber R, Sabin CA, Friis-Miller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A: D study. Arch Intern Med. 2006;166(15):1632–41.
7. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults co-infected with HIV/HCV. JAMA. 2012;308(4):370–8.
8. Sovaldi (package insert). Gilead Sciences, Inc.; Foster City, CA; 2014.
9. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.
10. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomized, multicentre phase 2 trial. Lancet. 2013;381:2100–7.
11. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.
12. Aptivus (package insert). Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield, CT; 2014.
13. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed Mar 19, 2015.
14. Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. 63rd Annual Meeting of the American Association of the Study of Liver Diseases (AASLD) 2012. Nov 9–11, 2012, 2013; Boston, MA. (Abstract).
15. Olysio (package insert). Janssen Therapeutics; Titusville NJ; 2013.
16. Izquierdo L, Helle F, François C, et al. Simeprevir for the treatment of hepatitis C virus infection. Pharmgenom Pers Med. 2014;7:241–9.
17. Atripla (package insert). Gilead Sciences, Inc.; Foster City, CA; 2013.
18. Tybost (package insert). Gilead Sciences, Inc.; Foster City, CA; 2012.
19. Stribild [package insert]. Gilead Sciences: Foster City, CA; August 2012.
20. University of California, San Francisco; HIV in-site website: http://hivinsite.ucsf.edu/insite?page=ar-0002&post=6¶m=25¶m=243. Accessed Dec 1, 2014.
21. Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers. Presented at Infectious Disease Society Association; San Diego, CA Oct 17-21-2012 (Abstract).
22. Harvoni (package insert). Gilead Sciences, Inc. Foster City, CA. October 2014.
23. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.
24. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736–743.e1.
25. German P, Pang PS, West S, et al. Drug interactions between direct-acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [Presentation]. Paper presented at: 15th international workshop on clinical pharmacology of HIV and hepatitis therapy; May 19–21, 2014; Washington DC.
26. Victrelis (package insert). MERCK & CO., Inc; Whitehouse Station, NJ; 2011.
27. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56(5):718–26.
28. Incivek (package insert). Vertex Pharmaceuticals (Canada) Incorporated; Laval, Quebec; 2013.
29. Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol. 2012;75:431–9.
30. Kakuda T, Leopold L, Nijs S. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomized, two-way crossover trial. 13th international workshop on clinical pharmacology of HIV therapy, Barcelona; 2012 (Abstract).
31. van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. 18th conference on retroviruses and opportunistic infections, Boston; 2011 (Abstract).
32. van Heeswijk R, Garg V, Boogaerts G, Vandebosch A, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51th ICAAC meeting, Chicago; 2011 (Abstract).
33. Copegus (package insert). Genentech, Inc; South San Francisco, CA; 2013.
34. Japour AJ, Lertora JJ, Meehan PM, et al. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:235–46.
35. Torriani FJ, Rodriguez-torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–50.
36. Foster GR. Pegylated interferon for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70(2):147–65.
37. Viekira Pak™ (package insert). AbbVie Inc.; North Chicago, IL; 2015.
38. Andreone P, Colombo M, Enejosa, JV, et al. PEARL-II: randomized phase 3 trial of interferon-free, 12-week regimen of ABT-450/r/ABT-267, ABT-333 with or without ribavirin in Hepatitis C virus genotype 1b-infected, treatment-experienced patients. Gastroenterology. 2104;146(5):S-159.
39. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–603.
40. Zeuzem S, Jacobson IM, Baykal T, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–16.
41. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2104;370(21):1983–1992.
42. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82.
43. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015.
44. Eron JJ, Lalezari J, Slim J, et al. Safety and efficacy of ombitasvir-450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. J Int AIDS Soc. 2014;17(4 Suppl 3):19500.
45. Khatri A, Wang T, Wang H, et al. Drug–drug interactions of the direct-acting antiviral regimen of ABT-450/r, ombitasvir, and dasabuvir with HIV protease inhibitors. [Abstract 484] 54th interscience conference on antimicrobial agents and chemotherapy (ICAAC). Sept 5–9, 2014; Washington, DC.
46. Khatri A, Wang T, Wang H, et al. Drug–drug interactions of the direct-acting antiviral regimen of ABT-450/r, ombitasvir, and dasabuvir with emtricitabine + tenofovir, raltegravir, rilpivirine and efavirenz. [Abstract 438] 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Sept 5–9, 2014; Washington, DC.